logo

Passion for Innovation. Compassion for Patients.™

Daiichi Sankyo Nordics ApSc/o

Olmesartan

In our portfolio since: 2002

Trademark: Olmetec, Sevikar, Sevikar HTC1

Indication:

High blood pressure is one of the most common causes of cardiovascular diseases in the world. Olmesartan is an angiotensin receptor blocker (ARB) with excellent blood pressure lowering efficacy. More than 5 million patients worldwide have been treated with this drug since 2002.2 Healthcare professionals around the world are demonstrating huge acceptance of Olmesartan. In Europe, there are a range of single pills available powered by Olmesartan from mono to triple combinations.

  • Olmetec: Olmetec belongs to a group of medicines known as angiotensin-II receptor antagonists. Angiotensin-II is a substance produced in the body which causes blood vessels to tighten. OLMETEC blocks the action of angiotensin-II and therefore relaxes your blood vessels. This helps lower the blood pressure.
  • ​Sevikar: Sevikaris a highly effective, once-daily, fixed-dose combination of olmesartan medoxomil (a highly effective ARB)3 and amlodipine-besilate (a widely used and clinically accepted calcium channel blocker)4 for the treatment of hypertension. SEVIKARdelivers powerful blood pressure lowering through a flexible and convenient once-daily single pill, allowing the majority of 'Challenging Patients*' to reach their target blood pressure.5 (Defined as any patient not reaching their goal blood pressure, with a minimum target of <140/90 mmHg.6)
  • ​Sevikar HTC: Sevikar HCT is indicated as substitution therapy in adult patients whose blood pressure is adequately controlled on the combination of olmesartan medoxomil, amlodipine and hydrochlorothiazide, taken as a dual-component (olmesartan medoxomil and amlodipine or olmesartan medoxomil and hydrochlorothiazide) and a single-component formulation (hydrochlorothiazide or amlodipine).

References

  1. For legal reasons detailed information about prescription medicine may only be given to healthcare professionals.
  2. IMS data end of 2014 on file with Daiichi Sankyo
  3. Redon J, Fabia MJ. Efficacy in angiotensin receptor blockade: a comparative review of data with olmesartan. J Renin Angiotensin Aldosterone Syst. 2009 Sep;10(3):147-56. Epub 2009 Aug 3
  4. Ohba T, Watanabe H, Murakami M, et al. Amlodipine inhibits cell proliferation via PKD1-related pathway. Biochem Biophys Res Commun. 2008 May 2;369(2):376-81. Epub 2008 Feb 25
  5. Chrysant SG, Melina M, Karki S, et al. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo controlled a-week factorial efficacy and safety study. Clin Ther 2008;30(4): 587-604.30:587-604
  6. Redon J, Brunner HR, Ferri C, et al. Practical solutions to the challenges of uncontrolled hypertension: a white paper. J Hypertens 2008;26(12):S1–S14